Clinical and Experimental Reproductive Medicine

  • 제40권2호
  • /
  • Pages.67-75
  • /
  • 2013
  • /
  • 2233-8233(pISSN)
  • /
  • 2233-8241(eISSN)
대한생식의학회 (The Korean Society for Reproductive Medicine)
권호 표지
DOI QR코드

DOI QR Code

Peroxisome proliferator-activated receptor ${\gamma}$ agonist suppresses human telomerase reverse transcriptase expression and aromatase activity in eutopic endometrial stromal cells from endometriosis

  • Chang, Hye Jin (Health Promotion Center, Seoul National University Bundang Hospital, Seoul National University College of Medicine) ;
  • Lee, Jae Hoon (Department of Obstetrics and Gynecology, Ajou University School of Medicine) ;
  • Hwang, Kyung Joo (Department of Obstetrics and Gynecology, Ajou University School of Medicine) ;
  • Kim, Mi Ran (Department of Obstetrics and Gynecology, Ajou University School of Medicine) ;
  • Yoo, Jung Hyun (Department of Obstetrics and Gynecology, Bundang Jesaeng Hospital)
  • 투고 : 2013.04.28
  • 심사 : 2013.06.03
  • 발행 : 2013.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: To investigate the effect of peroxisome proliferator activated receptor ${\gamma}$(PPAR${\gamma}$) agonist on the cell proliferation properties and expression of human telomerase reverse transcriptase (hTERT) and aromatase in cultured endometrial stromal cell (ESC) from patients with endometriosis. Methods: Human endometrial tissues were obtained from women with endometriosis and healthy women (controls) using endometrial biopsy. Isolated ESCs were cultured and the cell proliferation was measured by 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide assay and expression of hTERT, aromatase, and cyclooxygenase (COX)-2 by western blotting according to the addition of rosiglitazone (PPAR${\gamma}$ agonist). Results: We demonstrate that the cultured ESCs of endometriosis showed hTERT protein overexpression and increased cellular proliferation, which was inhibited by rosiglitazone, in a dose-dependent manner. At the same time, PPAR${\gamma}$ agonist also inhibited aromatase and COX-2 expression, resulting in decreased prostaglandin $E_2$ production in the ESCs of endometriosis. Conclusion: This study suggests that PPAR${\gamma}$ agonist plays an inhibitory role in the proliferative properties of eutopic endometrium with endometriosis by down-regulation of hTERT and COX-2 expression; this could be a new treatment target for endometriosis.

키워드

참고문헌

  1. Giudice LC, Kao LC. Endometriosis. Lancet 2004;364:1789-99. https://doi.org/10.1016/S0140-6736(04)17403-5
  2. Jones RK, Searle RF, Bulmer JN. Apoptosis and bcl-2 expression in normal human endometrium, endometriosis and adenomyosis. Hum Reprod 1998;13:3496-502. https://doi.org/10.1093/humrep/13.12.3496
  3. Starzinski-Powitz A, Gaetje R, Zeitvogel A, Kotzian S, Handrow- Metzmacher H, Herrmann G, et al. Tracing cellular and molecular mechanisms involved in endometriosis. Hum Reprod Update 1998;4:724-9. https://doi.org/10.1093/humupd/4.5.724
  4. Meresman GF, Vighi S, Buquet RA, Contreras-Ortiz O, Tesone M, Rumi LS. Apoptosis and expression of Bcl-2 and Bax in eutopic endometrium from women with endometriosis. Fertil Steril 2000; 74:760-6. https://doi.org/10.1016/S0015-0282(00)01522-3
  5. Noble LS, Takayama K, Zeitoun KM, Putman JM, Johns DA, Hinshelwood MM, et al. Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. J Clin Endocrinol Metab 1997;82:600-6.
  6. Tseng JF, Ryan IP, Milam TD, Murai JT, Schriock ED, Landers DV, et al. Interleukin-6 secretion in vitro is up-regulated in ectopic and eutopic endometrial stromal cells from women with endometriosis. J Clin Endocrinol Metab 1996;81:1118-22.
  7. Varma R, Rollason T, Gupta JK, Maher ER. Endometriosis and the neoplastic process. Reproduction 2004;127:293-304. https://doi.org/10.1530/rep.1.00020
  8. Lehner R, Enomoto T, McGregor JA, Shroyer AL, Haugen BR, Pugazhenthi U, et al. Quantitative analysis of telomerase hTERT mRNA and telomerase activity in endometrioid adenocarcinoma and in normal endometrium. Gynecol Oncol 2002;84:120-5. https://doi.org/10.1006/gyno.2001.6474
  9. Baykal A, Thompson JA, Xu XC, Hahn WC, Deavers MT, Malpica A, et al. In situ human telomerase reverse transcriptase expression pattern in normal and neoplastic ovarian tissues. Oncol Rep 2004; 11:297-302.
  10. Kim CM, Oh YJ, Cho SH, Chung DJ, Hwang JY, Park KH, et al. Increased telomerase activity and human telomerase reverse transcriptase mRNA expression in the endometrium of patients with endometriosis. Hum Reprod 2007;22:843-9. https://doi.org/10.1093/humrep/del425
  11. Kyo S, Kanaya T, Takakura M, Tanaka M, Inoue M. Human telomerase reverse transcriptase as a critical determinant of telomerase activity in normal and malignant endometrial tissues. Int J Cancer 1999;80:60-3. https://doi.org/10.1002/(SICI)1097-0215(19990105)80:1<60::AID-IJC12>3.0.CO;2-E
  12. Hapangama DK, Turner MA, Drury JA, Quenby S, Saretzki G, Martin- Ruiz C, et al. Endometriosis is associated with aberrant endometrial expression of telomerase and increased telomere length. Hum Reprod 2008;23:1511-9. https://doi.org/10.1093/humrep/den172
  13. Semple RK, Chatterjee VK, O'Rahilly S. PPAR gamma and human metabolic disease. J Clin Invest 2006;116:581-9. https://doi.org/10.1172/JCI28003
  14. Bruemmer D, Yin F, Liu J, Berger JP, Kiyono T, Chen J, et al. Peroxisome proliferator-activated receptor gamma inhibits expression of minichromosome maintenance proteins in vascular smooth muscle cells. Mol Endocrinol 2003;17:1005-18. https://doi.org/10.1210/me.2002-0410
  15. Tye BK. MCM proteins in DNA replication. Annu Rev Biochem 1999;68:649-86. https://doi.org/10.1146/annurev.biochem.68.1.649
  16. Ogawa D, Nomiyama T, Nakamachi T, Heywood EB, Stone JF, Berger JP, et al. Activation of peroxisome proliferator-activated receptor gamma suppresses telomerase activity in vascular smooth muscle cells. Circ Res 2006;98:e50-9. https://doi.org/10.1161/01.RES.0000218271.93076.c3
  17. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, et al. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998;58: 3344-52.
  18. Natarajan KR. Chemical inactivation of aflatoxins in peanut protein ingredients. J Environ Pathol Toxicol Oncol 1992;11:217-27.
  19. Demirturk F, Aytan H, Caliskan AC, Aytan P, Koseoglu DR. Effect of peroxisome proliferator-activated receptor-gamma agonist rosiglitazone on the induction of endometriosis in an experimental rat model. J Soc Gynecol Investig 2006;13:58-62. https://doi.org/10.1016/j.jsgi.2005.10.002
  20. Aytan H, Caliskan AC, Demirturk F, Aytan P, Koseoglu DR. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces the size of experimental endometriosis in the rat model. Aust N Z J Obstet Gynaecol 2007;47:321-5. https://doi.org/10.1111/j.1479-828X.2007.00744.x
  21. Chang HJ, Lee JH, Hwang KJ, Kim MR, Chang KH, Park DW, et al. Transforming growth factor (TGF)-beta1-induced human endometrial stromal cell decidualization through extracellular signalregulated kinase and Smad activation in vitro: peroxisome proliferator- activated receptor gamma acts as a negative regulator of TGF-beta1. Fertil Steril 2008;90:1357-65. https://doi.org/10.1016/j.fertnstert.2007.09.010
  22. Park DW, Choi DS, Ryu HS, Kwon HC, Joo H, Min CK. A well-defined in vitro three-dimensional culture of human endometrium and its applicability to endometrial cancer invasion. Cancer Lett 2003;195:185-92. https://doi.org/10.1016/S0304-3835(03)00131-9
  23. Han C, Demetris AJ, Liu Y, Shelhamer JH, Wu T. Transforming growth factor-beta (TGF-beta) activates cytosolic phospholipase A2alpha (cPLA2alpha)-mediated prostaglandin E2 (PGE)2/EP1 and peroxisome proliferator-activated receptor-gamma (PPAR-gamma)/ Smad signaling pathways in human liver cancer cells. A novel mechanism for subversion of TGF-beta-induced mitoinhibition. J Biol Chem 2004;279:44344-54. https://doi.org/10.1074/jbc.M404852200
  24. Kim JY, Choi JA, Kim TH, Yoo YD, Kim JI, Lee YJ, et al. Involvement of p38 mitogen-activated protein kinase in the cell growth inhibition by sodium arsenite. J Cell Physiol 2002;190:29-37. https://doi.org/10.1002/jcp.10049
  25. Harada T, Taniguchi F, Izawa M, Ohama Y, Takenaka Y, Tagashira Y, et al. Apoptosis and endometriosis. Front Biosci 2007;12:3140-51. https://doi.org/10.2741/2302
  26. Dmowski WP, Ding J, Shen J, Rana N, Fernandez BB, Braun DP. Apoptosis in endometrial glandular and stromal cells in women with and without endometriosis. Hum Reprod 2001;16:1802-8. https://doi.org/10.1093/humrep/16.9.1802
  27. Taylor RN, Lebovic DI, Mueller MD. Angiogenic factors in endometriosis. Ann N Y Acad Sci 2002;955:89-100. https://doi.org/10.1111/j.1749-6632.2002.tb02769.x
  28. Kim MR, Kim YA, Jo MY, Hwang KJ, Ryu HS. High frequency of endometrial polyps in endometriosis. J Am Assoc Gynecol Laparosc 2003;10:46-8. https://doi.org/10.1016/S1074-3804(05)60233-2
  29. Yan P, Benhattar J, Seelentag W, Stehle JC, Bosman FT. Immunohistochemical localization of hTERT protein in human tissues. Histochem Cell Biol 2004;121:391-7. https://doi.org/10.1007/s00418-004-0645-5
  30. Oshita T, Nagai N, Ohama K. Expression of telomerase reverse transcriptase mRNA and its quantitative analysis in human endometrial cancer. Int J Oncol 2000;17:1225-30.
  31. Huang JC, Liu DY, Yadollahi S, Wu KK, Dawood MY. Interleukin-1 beta induces cyclooxygenase-2 gene expression in cultured endometrial stromal cells. J Clin Endocrinol Metab 1998;83:538-41.
  32. Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 2005;57:359-83. https://doi.org/10.1124/pr.57.3.6
  33. Yoshino O, Osuga Y, Hirota Y, Koga K, Hirata T, Harada M, et al. Possible pathophysiological roles of mitogen-activated protein kinases (MAPKs) in endometriosis. Am J Reprod Immunol 2004; 52:306-11. https://doi.org/10.1111/j.1600-0897.2004.00231.x
  34. Bruemmer D, Blaschke F, Law RE. New targets for PPARgamma in the vessel wall: implications for restenosis. Int J Obes (Lond) 2005;29 Suppl 1:S26-30.
  35. Fan W, Yanase T, Morinaga H, Mu YM, Nomura M, Okabe T, et al. Activation of peroxisome proliferator-activated receptor-gamma and retinoid X receptor inhibits aromatase transcription via nuclear factor-kappaB. Endocrinology 2005;146:85-92. https://doi.org/10.1210/en.2004-1046
  36. Lebovic DI, Kir M, Casey CL. Peroxisome proliferator-activated receptor- gamma induces regression of endometrial explants in a rat model of endometriosis. Fertil Steril 2004;82 Suppl 3:1008-13. https://doi.org/10.1016/j.fertnstert.2004.02.148
  37. Lebovic DI, Mwenda JM, Chai DC, Mueller MD, Santi A, Fisseha S, et al. PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo- and drug-controlled study. Fertil Steril 2007;88:1108-19. https://doi.org/10.1016/j.fertnstert.2006.12.072
  38. Hornung D, Waite LL, Ricke EA, Bentzien F, Wallwiener D, Taylor RN. Nuclear peroxisome proliferator-activated receptors alpha and gamma have opposing effects on monocyte chemotaxis in endometriosis. J Clin Endocrinol Metab 2001;86:3108-14.
  39. Hornung D, Chao VA, Vigne JL, Wallwiener D, Taylor RN. Thiazolidinedione inhibition of peritoneal inflammation. Gynecol Obstet Invest 2003;55:20-4. https://doi.org/10.1159/000068952
  40. Kavoussi SK, Witz CA, Binkley PA, Nair AS, Lebovic DI. Peroxisomeproliferator activator receptor-gamma activation decreases attachment of endometrial cells to peritoneal mesothelial cells in an in vitro model of the early endometriotic lesion. Mol Hum Reprod 2009;15:687-92. https://doi.org/10.1093/molehr/gap061
  41. Pritts EA, Zhao D, Ricke E, Waite L, Taylor RN. PPAR-gamma decreases endometrial stromal cell transcription and translation of RANTES in vitro. J Clin Endocrinol Metab 2002;87:1841-4.
  42. Klinkner DB, Lim HJ, Strawn EY Jr, Oldham KT, Sander TL. An in vivo murine model of rosiglitazone use in pregnancy. Fertil Steril 2006;86:1074-9. https://doi.org/10.1016/j.fertnstert.2006.03.024
  43. Minge CE, Bennett BD, Norman RJ, Robker RL. Peroxisome proliferator- activated receptor-gamma agonist rosiglitazone reverses the adverse effects of diet-induced obesity on oocyte quality. Endocrinology 2008;149:2646-56. https://doi.org/10.1210/en.2007-1570
  44. Haddad GF, Jodicke C, Thomas MA, Williams DB, Aubuchon M. Case series of rosiglitazone used during the first trimester of pregnancy. Reprod Toxicol 2008;26:183-4. https://doi.org/10.1016/j.reprotox.2008.08.001
  45. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71. https://doi.org/10.1056/NEJMoa072761
  46. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8. https://doi.org/10.1001/jama.298.10.1180

피인용 문헌

  1. The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signalling vol.36, pp.suppl1, 2013, https://doi.org/10.1093/carcin/bgv030
  2. Rosiglitazone affects the progression of surgically-induced endometriosis in a rat model vol.23, pp.1, 2013, https://doi.org/10.3892/mmr.2020.11673
  3. Moracin D induces apoptosis in prostate cancer cells via activation of PPAR gamma/PKC delta and inhibition of PKC alpha vol.35, pp.12, 2021, https://doi.org/10.1002/ptr.7313